Fluzone High-Dose is an injected flu vaccine formulated for people age 65 years and older. Like other flu vaccines, Fluzone High-Dose is made up of the three flu strains most likely to cause the flu during the upcoming season. The high-dose vaccine, however, contains four times as much flu virus antigen — the part of the vaccine that stimulates the immune system — as regular Fluzone and other standard flu vaccines.
Why is it needed?
In response to a regular flu shot, older people produce 50 to 75 percent fewer antibodies, which protect against the vaccine antigens, than do younger adults.
Evidence that a high-dose flu vaccine can compensate for this difference originally comes from studies that found higher post-vaccine antibody levels in older people who received high-dose flu vaccine than in those who received standard flu vaccine.
In addition, one study found almost 25 percent fewer cases of proven influenza in adults age 65 and older who took the high-dose vaccine compared with those who took the standard-dose vaccine.
Are there side effects?
In the largest of three clinical studies comparing high-dose and standard-dose flu vaccine, those who received the high-dose vaccine were more likely to develop side effects, such as fever and soreness at the injection site, during the week after vaccination.
More research needed
The risks of flu complications are highest for people age 65 years and older, so protecting this group is particularly important. The Food and Drug Administration accelerated its approval of Fluzone High-Dose on the condition that studies will continue to evaluate the new vaccine's effect on seasonal flu outcomes, such as cases of flu and flu complications, in older people. If, over the next few years, Fluzone High-Dose turns out to be superior to regular flu vaccine by these measures, high-dose vaccine may become the vaccine of choice for older people.
Aug. 28, 2014
- Centers for Disease Control and Prevention, et al. Licensure of a high-dose inactivated influenza vaccine for persons >65 years of age (Fluzone High-Dose) and guidance for use — United States, 2010. MMWR. 2010;59:485. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5916a2.htm. Accessed June 20, 2014.
- Fluzone High-Dose seasonal influenza vaccine. Centers for Disease Control and Prevention. http://www.cdc.gov/flu/protect/vaccine/qa_fluzone.htm. Accessed June 20, 2014.
- Tsang P, et al. Immunogenicity and safety of Fluzone intradermal and high-dose influenza vaccines in older adults ≥ 65 years of age: A randomized, controlled, phase II trial. Vaccine. 2014;32:2507.
- Hibberd PL. Seasonal influenza vaccination in adults. http://www.uptodate.com/home. Accessed June 23, 2014.
- Reber AJ, et al. Immunosenescence and challenges of vaccination against influenza in the aging population. Aging and Disease. 2012;3:68.
- DiazGranados CA, et al. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: Safety, immunogenicity and relative efficacy during the 2009-2010 season. Vaccine. 2013;31:861.
- DiazGranados CA, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. The New England Journal of Medicine. 2014;371:635.